新しい抗凝固薬を巡る話題「心房細動に伴う血栓塞栓症予防と新しい抗凝固薬の役割」２．抗凝固薬の薬物動態と相互作用

スポンサーリンク

概要

• 論文の詳細を見る

• Vitamin K antagonists (VKA) such as warfarin are highly effective in preventing recurrent ischemic stroke of cardiac origin due to atrial fibrillation. During the last five decades, little progress has been made in the development of oral anticoagulants, and warfarin is the only oral anticoagulant currently recommended for the prevention of stroke in patients with moderate to high risk of stroke. Although effective, VKA have unpredictable pharmacologic effects, requiring regular coagulation monitoring and dose adjustment to maintain effects within the therapeutic range. These limitations increase the complexity of VKA use in the clinical setting, creating a burden for patients, physicians, and pharmacists. Therefore, the current focus of clinical development is on new oral anticoagulants that directly target thrombin or activated factor X(FXa). These new anticoagulants are more convenient than VKA, with predictable anticoagulant response, low potential of drug-drug interactions, and using fixed doses without coagulation monitoring. Recently, some of these drugs have been approved in the EU, Canada, and Japan for the prevention of thromboembolism in patients undergoing hip- and knee-replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, or prevention of cardiac events in patients with acute coronary syndromes. This review summarizes the pharmacokinetic properties and drug interactions of new anticoagulants (dabigatran etexilate, edoxaban, rivaroxaban, apixaban, idrabiotaparinux).

• 一般社団法人 日本臨床薬理学会の論文

一般社団法人 日本臨床薬理学会 | 論文

• 臨床家の立場より : 脳循環代謝改善薬
• 生体肝移植ならびに小腸移植術後のタクロリムス投与方法
• 甲状腺機能低下によりWarfarin効果の減弱がみられた症例
• 治験の品質管理における治験コーデイネーターの役割
• 治験,臨床試験,臨床研究とCRC

もっと見る

スポンサーリンク